Cannabics Pharmaceuticals Appoints a Second Independent Board Member

Rhea-AI Summary

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced the appointment of Dr. Gil Feiler as an Independent Director to its Board, having previously served as a Permanent Observer since October 2019. Dr. Feiler, a prominent economist, also leads the company's Advisory Board. His extensive experience includes senior roles in both academia and business sectors, with a focus on Middle East economics. This appointment follows the recent nomination of Dr. Inbar Maymon-Pomeranchik as another Independent Director, signaling a strengthening of the company's governance.

Positive

• Dr. Gil Feiler's appointment could enhance decision-making with his extensive experience.
• Strengthened governance with the addition of Dr. Feiler and Dr. Maymon-Pomeranchik.

Negative

• None.

TEL AVIV, Israel and BETHESDA, Maryland, July 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Gil Feiler to its Board of Directors as an Independent Director. Dr. Feiler, 62, who until now served as a Permanent Observer on the company's Board, is a world-renowned economist and currently serves also as the company's Head of Advisory Board. Dr. Feiler holds a PhD in Middle East Economics from Tel Aviv University, and is a graduate of the International Management Program at the Israeli Institute of Technology, Technion. Dr. Feiler currently serves also as Director of the Bank of Georgia for the Middle East and North Africa, as Partner at Forest Investment House ($1B AUM) and as Chairman of Seedo Corp (SEDO).

The announcement comes following the nomination, earlier this month, of another Independent Director to the company's Board, Dr. Inbar Maymon-Pomeranchik.

Cannabics Pharmaceuticals' co-founder and CEO Eyal Barad commented: "Dr. Gil Feiler has been with us as a Permanent Observer on the Board since October 2019. During that time, we could always count on his distinctive and informed perspective. Gil is a great addition to our Board of Directors; he is highly familiar with our business, and he is also the Head of our Advisory Board where he was able to assemble a team of multidisciplinary top-level experts that provide us counsel on key issues. I look forward to working with Gil in his new capacity as Independent Director, and I am certain that the company and its shareholders will enjoy the added benefit that he will bring to the table, now with an even greater level of engagement".

Dr. Gil Feiler commented: "It is a great honor to join the company as an Independent Director. I have been working closely with CEO Barad and President Yariv for almost two years now, and I have full confidence in their leadership and their determination to move this company forward and onto the clinical and commercial success".

About Dr. Gil Feiler:

During 20 years in academia, Dr. Feiler taught Business, Economics, and Middle East Studies as an Associate Professor at Tel Aviv University, Bar Ilan University and at the Interdisciplinary Center Herzlia. He has extensive senior executive business experience in both small and large companies, including Coca Cola Israel; he is founder of the largest news portal in the Arabic world, and has served on the board of The First International Bank of Israel, Mutual Fund Division; Dr. Feiler also served as Special Business Advisor to the Government of Ras al-Khemah, United Arab Emirates.

Dr. Feiler is an Alumni of the US State Department International Visitor Leadership Program (1997), and has also published extensively on business opportunities in the Middle East, on Political Economy, on Economic Cooperation, and on Financing of Terrorism. He is also the author of several books including: Rethinking Business Strategy for the Middle East and North Africa (London: The Economist, 1997); From Boycott to Economic Cooperation: An Analysis of the Arab Boycott of Israel (London: Frank Cass: 1998), The Middle East in the New Millennium (New York: Kluwer Law International, 2000), Economic Relations Between Egypt and the Gulf Oil States: Petro-Wealth and Patterns of Influence (Brighton: Sussex Academic Press, 2003), and Investing in Russia, the Ukraine, Latvia, Lithuania and Kazakhstan (Portland: Sussex Academic Press, 2007) (co-authored with Alexandre Garese).

Dr. Feiler delivered papers at the UN, at Harvard conferences and at the World Economic Forum in Davos.

About Cannabics Pharmaceuticals:

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

Disclaimer:

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.

For more information about Cannabics:

Cannabics Pharmaceuticals Inc.
Phone: +1-(877)-424-2429
info@Cannabics.com

http://www.Cannabics.com

Logo - https://mma.prnewswire.com/media/796838/Cannabics_Pharmaceuticals_Logo.jpg

 

 

 

 

 

View original content:https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-appoints-a-second-independent-board-member-301337365.html

SOURCE Cannabics Pharmaceuticals Inc.

FAQ

What is the significance of Dr. Gil Feiler's appointment to Cannabics Pharmaceuticals?

Dr. Gil Feiler's appointment as Independent Director is significant as he brings extensive expertise in economics and business, which can enhance the company's strategic decision-making.

Who are the new members of the Cannabics Pharmaceuticals Board of Directors?

The new members of Cannabics Pharmaceuticals' Board include Dr. Gil Feiler and Dr. Inbar Maymon-Pomeranchik, both serving as Independent Directors.

How long has Dr. Gil Feiler been associated with Cannabics Pharmaceuticals before his appointment?

Dr. Gil Feiler has been associated with Cannabics Pharmaceuticals as a Permanent Observer on the Board since October 2019.

What roles does Dr. Gil Feiler hold in addition to being an Independent Director?

In addition to being an Independent Director, Dr. Gil Feiler serves as the Head of the Advisory Board and has extensive executive experience in the business sector.

What impact could the new board appointments have on Cannabics Pharmaceuticals?

The new board appointments could lead to improved governance and strategic direction for Cannabics Pharmaceuticals, potentially enhancing its clinical and commercial success.